Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
6.02
-0.04 (-0.58%)
At close: Aug 1, 2025, 4:00 PM
6.10
+0.08 (1.41%)
After-hours: Aug 1, 2025, 5:22 PM EDT

Company Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors.

It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC.

The company is headquartered in San Diego, California.

Kura Oncology, Inc.
Kura Oncology logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees192
CEOTroy Wilson

Contact Details

Address:
12730 High Bluff Drive, Suite 400
San Diego, California 92130
United States
Phone858 500 8800
Websitekuraoncology.com

Stock Details

Ticker SymbolKURA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001422143
CUSIP Number50127T109
ISIN NumberUS50127T1097
Employer ID61-1547851
SIC Code2834

Key Executives

NamePosition
Dr. Troy Edward Wilson J.D., Ph.D.Chairman, Chief Executive Officer and President
Kathleen FordChief Operating Officer
Teresa Brophy Bair Esq., J.D.Chief Legal Officer and Corporate Secretary
Thomas DoyleSenior Vice President of Finance and Accounting
Dr. Francis J. Burrows Ph.D.Chief Scientific Officer
Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing and Supply Chain
Maureen Clancy M.B.A.Vice President and Global Head of Program Leadership and Project Management
Dr. Mollie Leoni M.D.Chief Medical Officer
Brian T. Powl M.B.A., M.S.Chief Commercial Officer
Samir Vattompadam M.S.Senior Vice President of Global Program Leadership

Latest SEC Filings

DateTypeTitle
Jul 1, 20258-KCurrent Report
Jun 18, 20258-KCurrent Report
Jun 6, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 6, 20258-KCurrent Report
Jun 3, 20258-KCurrent Report
May 19, 2025144Filing
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 2, 2025SCHEDULE 13G/AFiling
May 1, 202510-QQuarterly Report